Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judit Moldvay

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
International Journal of Cancer|August 14, 2019
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progressionJulian Mohrherr, Marcel Haber, Kristina Breitenecker, et al.
Cancers|October 12, 2019
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based ChemotherapyAron Kristof Ghimessy, Aron Gellert, Erzsebet Schlegl, et al.
Magyar Onkologia|October 5, 2021
[Heterogeneity of small cell lung cancer: biological and clinicopathological implications]Zsolt Megyesfalvi, Nándor Bárány, Zsuzsanna Valkó, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2020
Lung Cancer in HungaryKrisztina Bogos, Zoltán Kiss, Gabriella Gálffy, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort studyThomas Klikovits, Zoltán Lohinai, Katalin Fábián, et al.
Pathology Oncology Research : POR|July 14, 2021
Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016Lilla Tamási, Krisztián Horváth, Zoltán Kiss, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapyMihaly Cserepes, Gyula Ostoros, Zoltan Lohinai, et al.
Pathology Oncology Research : POR|July 14, 2021
Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011-2016Krisztina Bogos, Zoltan Kiss, Lilla Tamási, et al.
Pathology Oncology Research : POR|January 10, 2022
Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From HungaryZoltan Kiss, Krisztina Bogos, Lilla Tamási, et al.
Science Translational Medicine|July 8, 2021
Down-regulation of A20 promotes immune escape of lung adenocarcinomasKristina Breitenecker, Monika Homolya, Andreea C Luca, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
International Journal of Cancer|August 14, 2019
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progressionJulian Mohrherr, Marcel Haber, Kristina Breitenecker, et al.
Cancers|October 12, 2019
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based ChemotherapyAron Kristof Ghimessy, Aron Gellert, Erzsebet Schlegl, et al.
Magyar Onkologia|October 5, 2021
[Heterogeneity of small cell lung cancer: biological and clinicopathological implications]Zsolt Megyesfalvi, Nándor Bárány, Zsuzsanna Valkó, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2020
Lung Cancer in HungaryKrisztina Bogos, Zoltán Kiss, Gabriella Gálffy, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort studyThomas Klikovits, Zoltán Lohinai, Katalin Fábián, et al.
Pathology Oncology Research : POR|July 14, 2021
Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016Lilla Tamási, Krisztián Horváth, Zoltán Kiss, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapyMihaly Cserepes, Gyula Ostoros, Zoltan Lohinai, et al.
Pathology Oncology Research : POR|July 14, 2021
Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011-2016Krisztina Bogos, Zoltan Kiss, Lilla Tamási, et al.
Pathology Oncology Research : POR|January 10, 2022
Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From HungaryZoltan Kiss, Krisztina Bogos, Lilla Tamási, et al.
Science Translational Medicine|July 8, 2021
Down-regulation of A20 promotes immune escape of lung adenocarcinomasKristina Breitenecker, Monika Homolya, Andreea C Luca, et al.
Pageof 11